The Coordination and Support Action (CSA) BrainHealth will lay the ground for an envisaged ‘European Partnership (EP) on Brain Health’. Twenty participants from 11 Member and Associated States and Third countries will jointly pursue the work plan. The overall objective of the CSA is to sizeably contribute to maintenance and restoration of brain health for citizens in Europe and worldwide. Specifically, the project aims to design a collaboration framework for the EP as an umbrella for existing initiatives and stakeholder communities in this area. The CSA will create a common understanding of achievements, gaps and future developments in European research into brain health, and derive from them priorities and opportunities in a Strategic Research and Innovation Agenda (SRIA). Intense consultation with representatives of Member and Associated States is expected to lead to adoption of the SRIA and development of an implementation plan that will allow for strategic alignment of regional and national research programmes and commitments to the EP. Research infrastructures and platforms will be analysed regarding their service opportunities, and solutions will be developed to facilitate data and material sharing in the area of brain health. For highest possible impact, the CSA will reach out to the most relevant globally acting initiatives and their brain research strategies and policies. Synergies will be identified to shape the international landscape and establish new while maintaining existing collaboration. Finally, the CSA activities will be embedded in thoroughly planned dissemination and communication activities and an efficient management structure.

At the highest political levels antimicrobial resistance (AMR) is recognised as major threat to the health of citizens and societies, food security and development as it threatens the effective prevention and treatment of infections and thus the attainment of the Sustainable Development Goals. Global cooperation to address AMR with a one health approach is needed to tackle increasing levels of AMR in bacteria, fungi, viruses and parasites, which present a major threat to human, animal, plant and environmental health. DESIGN OH AMR aims to promote a one health response to link the multisectoral AMR research and innovation landscape. The DESIGN OH AMR will lay the preparatory groundwork of the candidate European co-funded partnership on OH AMR by addressing the ?European One Health Action Plan against AMR?. It will develop the strategic basis for the OH AMR partnership through engaging with, and building on, networks of research funders, policy makers, relevant agencies, European partnerships under the Horizon 2020 Framework Programme, and authorities to strengthen coordination and collaboration among different fields of research and innovation with relevance to AMR.

In order to strengthen the global efforts on Personalized Medicine (PerMed) and the cooperation of the EU-CELAC countries to them, a unique Bi-regional consortium of governmental and funding organisations is shaped with the support of leading stakeholders as associated partners. This project has the ambition to engage CELAC countries in the International Consortium on Personalized Medicine (ICPerMed) and in the ERANet ERAPerMed with the aim at advancing in the implementation of the Action Plan of ICPerMed based in the Strategic Research and Innovation Agenda, drafted by PerMed2020. Research on PerMed is a top priority for the EU as a strategy aimed at delivering personalised health and care solutions to benefit citizens. Results of R&I actions will generate and translate knowledge on disease aetiology and technological innovation into personalised health and care solutions. Areas of application include chronic, rare and communicable diseases. Research under this priority will also attempt to develop an outstanding economic impact due to the potential of PerMed to transform health systems. The collaboration of diverse actors from different world regions, disciplines and health-care systems are needed to implement in a holistic way new feasible and cost-effective PerMed approaches. Involvement in ICPerMed of RFOs and policy-making bodies from EU and from other regions, is the best way to push forward the impact of new findings and knowledge in the area. This CSA will be the vehicle for: i) Mapping existing programmes, capacities and expertise and gaps in CELAC countries; ii) Facilitating the incorporation of CELAC countries in ICPerMed and in the ERAPerMed; iii) Fostering the participation of CELAC countries in research mobility and transnational projects on PerMed, and a platform for EU‐CELAC collaboration on clinical trials PerMed focused; iv) Cross-border learning from R&I and ELSA for implementing innovations between research capacities based in EU and CELAC.